Risk of Renal or Urinary Related Hospitalization in Survivors of Childhood Cancer: Results from the French Childhood Cancer Survivor Study.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
03 04 2023
Historique:
received: 25 08 2022
revised: 21 10 2022
accepted: 19 01 2023
medline: 4 4 2023
pubmed: 25 1 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

Hospitalization rates can be used as an indirect indicator of the burden and severity of adverse health outcomes in childhood cancer survivors (CCS). We aimed to determine the long-term risks of hospitalization related to renal and urinary diseases among 5-year CCS. The French Childhood Cancer Survivor Study cohort was linked with data from the French National Healthcare System database, which enabled the identification of hospitalizations related to renal or urinary diseases. Clinical and detailed treatment data were collected from medical records. Dose-volume histograms were estimated for all patients treated with radiotherapy. Standardized Hospitalization Ratios and absolute excess risks (AER) were calculated. Relative risks were estimated using Poisson regression. A total of 5,498 survivors were followed for 42,118 person-years (PY). Survivors experience 2.9 times more renal hospitalizations than expected in the general population, with an AER of 21.2/10,000 PY. Exposing more than 10% of the kidneys' volume to at least 20 Gray increases the risk of being hospitalized for renal causes by 2.2 (95% confidence interval, 1.3-3.6). Nephrectomized survivors treated with high doses of ifosfamide (>60 g/m²) have an extremely high risk of hospitalization for renal causes. Patients with comorbidities have about a 3-fold higher risk, and nephrectomized patients a 2-fold higher risk of being hospitalized for renal causes compared with other subjects. In the case of hospitalization for urinary causes, treatment by anthracycline administration was found to be associated with an almost 2-fold higher risk of hospitalization compared with the general population. These results support the need for careful monitoring of long-term renal diseases in survivors who have undergone nephrectomy, those treated with high doses of radiation (≥20 Gy) even to small volumes of the kidneys, and those with predisposing risk factors. This study provides new evidence with potential impact on surveillance guidelines related to dose-volume indicators associated with renal toxicity.

Sections du résumé

BACKGROUND
Hospitalization rates can be used as an indirect indicator of the burden and severity of adverse health outcomes in childhood cancer survivors (CCS). We aimed to determine the long-term risks of hospitalization related to renal and urinary diseases among 5-year CCS.
METHODS
The French Childhood Cancer Survivor Study cohort was linked with data from the French National Healthcare System database, which enabled the identification of hospitalizations related to renal or urinary diseases. Clinical and detailed treatment data were collected from medical records. Dose-volume histograms were estimated for all patients treated with radiotherapy. Standardized Hospitalization Ratios and absolute excess risks (AER) were calculated. Relative risks were estimated using Poisson regression.
RESULTS
A total of 5,498 survivors were followed for 42,118 person-years (PY). Survivors experience 2.9 times more renal hospitalizations than expected in the general population, with an AER of 21.2/10,000 PY. Exposing more than 10% of the kidneys' volume to at least 20 Gray increases the risk of being hospitalized for renal causes by 2.2 (95% confidence interval, 1.3-3.6). Nephrectomized survivors treated with high doses of ifosfamide (>60 g/m²) have an extremely high risk of hospitalization for renal causes. Patients with comorbidities have about a 3-fold higher risk, and nephrectomized patients a 2-fold higher risk of being hospitalized for renal causes compared with other subjects. In the case of hospitalization for urinary causes, treatment by anthracycline administration was found to be associated with an almost 2-fold higher risk of hospitalization compared with the general population.
CONCLUSIONS
These results support the need for careful monitoring of long-term renal diseases in survivors who have undergone nephrectomy, those treated with high doses of radiation (≥20 Gy) even to small volumes of the kidneys, and those with predisposing risk factors.
IMPACT
This study provides new evidence with potential impact on surveillance guidelines related to dose-volume indicators associated with renal toxicity.

Identifiants

pubmed: 36692978
pii: 716153
doi: 10.1158/1055-9965.EPI-22-0925
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-581

Informations de copyright

©2023 American Association for Cancer Research.

Auteurs

Imene Mansouri (I)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.

Boris Schwartz (B)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.

Giao Vu-Bezin (G)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.

Daniel Bejarano-Quisoboni (D)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.
Primary Care and Prevention Team, CESP, Inserm U1018, Villejuif, France.

Brice Fresneau (B)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.
Department of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Chiraz El-Fayech (C)

Department of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Christelle Dufour (C)

Department of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Stéphanie Bolle (S)

Department of Radiotherapy Oncology, Gustave Roussy Paris-Saclay University, Paris, France.

Aurore Surun (A)

SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.

Daniel Orbach (D)

SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.

Rodrigue S Allodji (RS)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.

Ibrahima Diallo (I)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.
Primary Care and Prevention Team, CESP, Inserm U1018, Villejuif, France.

Charlotte Demoor-Goldschmidt (C)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Department of Radiotherapy, Centre François Baclesse, Caen, France.
Department of Pediatric Immunology/Hematology/Oncology, University Hospital of Angers, Angers, France.

Florent de Vathaire (F)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.

Nadia Haddy (N)

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Université Paris-Saclay, Inserm, CESP, 94807, Villejuif, France.
Department of Research, Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH